Market analysis


Market analysis seeks to understand the dynamics of markets, with the goal of informing business strategies. For example, analysis of the current and potential future markets for drugs to treat particular diseases is used by pharmaceutical companies in decisions about where to invest in drug research and development.

Latest Research and Reviews

  • Research |

    Although investment in pharmaceutical research and development (R&D) has increased substantially in recent decades, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, Riccaboni and colleagues examine the factors underlying the decline in R&D productivity, which include an increasing concentration of R&D investments in areas in which the risk of failure is high.

    • Fabio Pammolli
    • , Laura Magazzini
    •  & Massimo Riccaboni

News and Comment

  • News |

    The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development.

    • Eleni Pantazi
    • , Gianluca Valenza
    • , Manuela Hess
    •  & Bashar Hamad
  • News |

    This article discusses the impact of new drugs on the market for multiple sclerosis, including the recently approved immunomodulatory drug ocrelizumab and drugs in development such as sphingosine 1-phosphate receptor modulators and neurorestorative agents.

    • Anders Westad
    • , Aditya Venugopal
    •  & Eric Snyder
  • News |

    This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.

    • Jennifer Bamford
    •  & Rachel M. Webster
  • News |

    The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.

    • Sorcha Cassidy
    •  & Basharut A. Syed
  • News |

    Two PD-1 directed checkpoint inhibitors have recently been approved for squamous cell carcinoma of the head and neck (SCCHN). Further checkpoint inhibitors, as well as other molecularly targeted agents and cytokine-based immunotherapies, are currently in the late-stage pipeline and are poised to change the treatment paradigm for SCCHN.

    • Jennifer Bamford
    •  & Rachel M. Webster